|
MechanismGluN2B antagonists |
Active Org.- |
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, Randomized, Double Blind, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of NP10679 in Healthy Adults"
This multiple ascending dose study assesses the safety, tolerability and pharmacokinetics of NP10679 when delivered intravenously in escalating dose levels in comparison to placebo.
A Phase 1, Randomized , Double Blind, Single Ascending Dose Study to Investigate Safety, Tolerability and PK of NP10679 in Healthy Adults
This study assesses the safety, tolerability and pharmacokinetics of NP10679 when delivered intravenously in escalating dose levels in comparison to placebo.
100 Clinical Results associated with NeurOp, Inc.
0 Patents (Medical) associated with NeurOp, Inc.
2012·Annual Reports in Medicinal Chemistry
NMDA antagonists of GluN2B subtype and modulators of GluN2A, GluN2C, and GluN2D subtypes-recent results and developments
Author: Ruppa, Kamalesh B. ; King, Dalton ; Olson, Richard E.
A review presents recent medicinal chem. advances in the area of GluN2B receptors, and emerging antagonists and modulators of other NMDA receptor subtypes.
100 Deals associated with NeurOp, Inc.
100 Translational Medicine associated with NeurOp, Inc.